PTEN and prostate carcinoma: To establish cell lines with acquired resistance both to ipatasertib/GDC-0068 and to MK-2206, we started with the LNCaP prostate cancer cell line, which is PTEN-deficient and intrinsically sensitive to both AKTis with similar IC50s (Supplementary Fig. 1a, b).